About Us
Our mission is to empower people living with neuromuscular diseases to live longer, more independent lives.
Statement from the Muscular Dystrophy Association on the FDA Decision Not to Approve Deramiocel for Duchenne Muscular Dystrophy
New York, NY – Saturday, November 21, 2026 – The U.S. Food and Drug Administration (FDA) has declined to approve deramiocel, an investigational cell therapy developed by Capricor Therapeutics for the treatment of Duchenne muscular dystrophy (DMD). The agency issued a Complete Response Letter (CRL), determining that the available clinical evidence did not meet the requirements for approval and identifying concerns about the reliability of clinical trial data.
The decision follows a lengthy regulatory review that included a previous CRL in July 2025, a public advisory committee meeting in July 2026, and the submission of a major amendment to the Biologics License Application (BLA) with additional open-label extension data and a proposed change in indication from cardiomyopathy to upper limb function. In a separate public statement, the FDA identified serious deficiencies in the conduct of the Phase 3 HOPE-3 study that, in its assessment, compromised the reliability of the clinical trial data.
Capricor has disputed the FDA's assessment of its clinical evidence and is evaluating its next steps. Deramiocel remains an investigational therapy and is not FDA-approved for the treatment of Duchenne muscular dystrophy.
We know this decision is a heavy blow for the Duchenne community, and our hearts are with the families who have waited, hoped, and fought for a new treatment. We are grateful to the FDA for its thorough review and to Capricor for its continued fight to bring a treatment to this community. We have deep appreciation for the clinicians who conducted the studies, and most importantly, the families and young people who participated in the deramiocel clinical trials. The FDA has referenced data integrity issues and deficiencies in the HOPE-3 trial in their statement, and thus the Muscular Dystrophy Association (MDA) seeks to learn more and will report back to the community as more information becomes available.
MDA recognizes the urgent need for additional treatment options for people living with Duchenne, particularly therapies that may help preserve cardiac and skeletal muscle function. While the development of new treatments presents significant scientific and regulatory challenges, reliable clinical evidence is essential to determining whether a therapy is safe and effective. MDA will seek to work with Capricor, as well as other advocates in the community, to better understand next steps and options for the continued development of deramiocel and will support the community in every way we can. We remain committed to accelerating research, advancing access to specialized care, and advocating for regulatory processes that recognize the urgency of unmet medical needs while maintaining appropriate standards for safety and effectiveness. We will follow all developments related to deramiocel and share relevant information with the Duchenne community as it becomes available.
We will continue to stand with the Duchenne community through this moment and in the work ahead.
Sincerely,
Sharon Hesterlee, PhD
President and Chief Executive Officer
Muscular Dystrophy Association
Jodi Wolff, PhD, MSSW
Chief Mission Officer
Muscular Dystrophy Association
Angela Lek, PhD
Chief Research Officer
Muscular Dystrophy Association
Read more:
MDA Support
For more information on SMA, and ongoing support for families and medical professionals, contact the MDA Resource Center by phone 1-833-ASK-MDA1 (1-833-275-6321) or email ResourceCenter@mdausa.org.
Media contact: press@mdausa.org
About Muscular Dystrophy Association
Muscular Dystrophy Association (MDA) has been at the center of progress for people living with muscular dystrophy, ALS, and over 300 other neuromuscular conditions for over 75 years. We unite researchers, clinicians, advocates, and families to speed the pace of discovery, improve access to expert care, and ensure inclusion in every aspect of life. Our mission is simple: give the people we serve the tools and opportunities to live longer, more independent lives. To learn more visit mda.org. Follow MDA on social media on Instagram, Facebook, X, TikTok, LinkedIn, and YouTube.